Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 8068

Next Previous
X
Search
Drug Profile

SHR 8068

Alternative Names: SHR-8068

Latest Information Update: 29 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver cancer
  • Phase II Biliary cancer; Gastric cancer; Oesophageal cancer
  • Phase I/II Non-small cell lung cancer; Urogenital cancer

Most Recent Events

  • 04 Nov 2024 Phase-I/II clinical trials in Urogenital cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (Parenteral) (NCT06639347)
  • 28 Oct 2024 Phase-III clinical trials in Liver cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, First-line therapy, Combination therapy) in China (IV) (NCT06618664)
  • 15 Oct 2024 Shanghai Hengrui Pharmaceutical plans a phase Ib/II trial for Urogenital cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Combination therapy) in China (NCT06639347)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top